New imaging AI tool hits market with reimbursement eligibility
A new artificial intelligence-enabled plaque analysis tool is now commercially available in the U.S. and comed with reimbursement eligibility.
Elucid—a Boston-based AI technology company that specializes in cardiovascular solutions—on Wednesday announced the commercial launch of its new Lesion Inspection Tool for coronary and carotid plaque analysis. The product, which is available within Elucid’s novel Plaque-IQ software suite, allows physicians to analyze and quantify lesion composition and plaque burden across any vessel, offering a clearer picture of patients’ cardiovascular risk.
It has been trained and validated against objective ground truth histology—the only commercially available, FDA-cleared plaque analysis tool to have done so. This training has made the software useful for quantifying high-risk features like lipid-rich necrotic core, arming clinicians with the information needed to make better treatment plans for patients.
“The Lesion Inspection Tool provides a detailed view of plaque composition at the lesion level, beyond giving just overall plaque metrics,” Jimmy Kerrigan, MD, an interventional cardiologist with Ascension Saint Thomas Heart, said in a statement.
Elucid’s Plaque-IQ software was cleared by the U.S. Food and Drug Administration in October of 2024. As of January, it has become eligible for reimbursement through the Current Procedural Terminology (CPT) code 75577. The code is assigned to AI software that provides quantification and characterization of coronary atherosclerotic plaque.
Read more here.
In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She began covering the medical imaging industry for Innovate Healthcare in 2021.